Berdagang Amgen AMGN

Jual
 Beli

Amgen carta live

5m 15m 30m 1h 4h 1d 1w

Asas Instrumen

Weekly Search
Weekly
Daily
Tarikh Tutup Perubahan Perubahan (%): Buka Tinggi Rendah

Amgen news

Frances Wang 2024 Nov 26, 16:00

Stock Market Today: S&P 500 and Dow Reach New High On Trump’s Tariff Policy

Stocks
Frances Wang 2024 Aug 04, 16:00

The Week Ahead: ISM services, SMCI

CFD Trading
Australian dollar shrugs at RBA decision to keep interest rates unchanged
Georgy Istigechev 2024 Aug 03, 21:00

Week ahead: RBA meeting, Uber earnings, and PMIs

CFD Trading Forex
Disney is catching up with Netflix
Neil Wilson 2024 Feb 01, 08:03

Week ahead: Earnings season climax

Forex Indices
Bank of England BoE
Neil Wilson 2023 Oct 27, 10:00

Week ahead: Fed, Bank of England seen on pause; Apple earnings

Forex Indices

Berita Terkini

Tunjukkan lebih lagi
Ava Grace 2025 Sep 12, 12:20

Poland Rejects Trump's 'Mistake' Claim on Drone Incursion, Calls it 'Deliberate Russian Attack'

Noah Lee 2025 Sep 12, 10:20

US-Japan Joint Statement: Reaffirming Market-Driven Exchange Rates

Emma Rose 2025 Sep 12, 09:20

Goldman Sachs, UBS Raise Gold Price Forecasts for 2025

Noah Lee 2025 Sep 12, 09:20

Albania Appoints AI Minister to Combat Corruption in Public Procurement

Emma Rose 2025 Sep 11, 15:20

Dalio: Gold as a Hedge Against Mounting Debt Risks

Ava Grace 2025 Sep 11, 14:20

Switzerland Proposes US Gold Refinery to Reduce Tariffs

Noah Lee 2025 Sep 11, 14:20

NATO and EU on Edge After Russian Drone Enters Poland: A Critical Test

Liam James 2025 Sep 11, 10:20

Economists Anticipate BOJ Rate Hike in Q4 Amidst Global Uncertainties

Maklumat

Sebaran nilai

3.07

Spread (%)

1.0997 %

Leveraj

1:10

Faedah semalaman (Beli)

-0.0597 %

Faedah semalaman (Jual)

-0.0292 %

Mata wang

USD

Waktu perdagangan

Pasaran dibuka

Jumaat

13:31 - 19:59

Isnin

13:31-19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Khamis

13:31-19:59

Analisis dan statistik

Buka

---

Tutup Terdahulu

---

Tinggi/Rendah 52 Minggu

--- – ---

Modal pasaran

152211095552

Saham Tertunggak

538361984

Tarikh Pendapatan (Seterusnya)

1999-11-22

Hasil Div

2025-09-12

Tarikh Selepas Dividen

2025-08-22

Kadar dividen tahunan depan

9.52

Hasil dividen tahunan depan

0.0337

EPS

12.24

Ketahui lebih lanjut mengenai instrumen ini

Amgen Amgen Inc
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Instrumen Berkaitan

Aset
Jual
Beli
Perubahan (%):

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang

Berdaganglah Sekarang
Instrumen Berkaitan

latest_education_articles

Tunjukkan lebih lagi
Trustpilot